JP2015504299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504299A5 JP2015504299A5 JP2014538724A JP2014538724A JP2015504299A5 JP 2015504299 A5 JP2015504299 A5 JP 2015504299A5 JP 2014538724 A JP2014538724 A JP 2014538724A JP 2014538724 A JP2014538724 A JP 2014538724A JP 2015504299 A5 JP2015504299 A5 JP 2015504299A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion
- protein
- fusion protein
- ret
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 25
- 102000037865 fusion proteins Human genes 0.000 claims 25
- 230000004927 fusion Effects 0.000 claims 19
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 210000000349 chromosome Anatomy 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 8
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 claims 7
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000003745 diagnosis Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229940127513 Fusion Protein Inhibitors Drugs 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229960001292 cabozantinib Drugs 0.000 claims 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 229940125874 fusion protein inhibitor Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553483P | 2011-10-31 | 2011-10-31 | |
| US61/553,483 | 2011-10-31 | ||
| US13/663,565 | 2012-10-30 | ||
| US13/663,565 US10023855B2 (en) | 2011-10-31 | 2012-10-30 | Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker |
| PCT/KR2012/009056 WO2013066047A1 (en) | 2011-10-31 | 2012-10-31 | Fusion protein comprising c-terminal domain of ret protein and use thereof as a diagnosing marker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504299A JP2015504299A (ja) | 2015-02-12 |
| JP2015504299A5 true JP2015504299A5 (https=) | 2015-12-03 |
| JP6389124B2 JP6389124B2 (ja) | 2018-09-12 |
Family
ID=48192340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014538724A Active JP6389124B2 (ja) | 2011-10-31 | 2012-10-31 | Ｒｅｔ蛋白質のｃ−末端ドメインを含む融合蛋白質及びその診断マーカーとしての用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10023855B2 (https=) |
| EP (1) | EP2773673B1 (https=) |
| JP (1) | JP6389124B2 (https=) |
| KR (2) | KR101660235B1 (https=) |
| WO (1) | WO2013066047A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3564261B1 (en) | 2011-08-23 | 2024-11-13 | Foundation Medicine, Inc. | Kif5b-ret fusion molecules and uses thereof |
| CN114129566A (zh) * | 2012-09-07 | 2022-03-04 | 埃克塞里艾克西斯公司 | 用于治疗肺腺癌的met、vegfr和ret的抑制剂 |
| SI2902029T1 (sl) | 2012-09-25 | 2018-11-30 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor ret |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| JP7033143B2 (ja) * | 2017-08-21 | 2022-03-09 | 大鵬薬品工業株式会社 | Ｄｃｔｎ１タンパク質とｒｅｔタンパク質との融合タンパク質 |
| SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
| JP2023527412A (ja) | 2020-05-29 | 2023-06-28 | ブループリント メディシンズ コーポレイション | プラルセチニブの固体形態 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1163509C (zh) | 1996-05-08 | 2004-08-25 | 拜奥根有限公司 | 刺激神经和肾生长的RET配体(RetL) |
| AU2001281136A1 (en) | 2000-08-04 | 2002-02-18 | Board Of Regents, The University Of Texas System | Detection and diagnosis of smoking related cancers |
| WO2005044086A2 (en) | 2003-10-30 | 2005-05-19 | Tufts-New England Medical Center | Prenatal diagnosis using cell-free fetal dna in amniotic fluid |
| EP1941909A4 (en) | 2005-10-24 | 2012-05-23 | Takeda Pharmaceutical | PREVENTIVE MEASURES / REMEDIES FOR CANCER |
| WO2008031551A2 (en) | 2006-09-12 | 2008-03-20 | Novartis Forschungsstiftung, Zweigniederlassung | Non-neuroendocrine cancer therapy |
| US20130137111A1 (en) | 2010-07-26 | 2013-05-30 | Astellas Pharma Inc. | Detection method of novel ret fusion |
| EP2740742B1 (en) | 2011-08-04 | 2018-03-14 | National Cancer Center | Fusion gene of kif5b gene and ret gene, and method for determining effectiveness of cancer treatment targeting fusion gene |
| EP3564261B1 (en) * | 2011-08-23 | 2024-11-13 | Foundation Medicine, Inc. | Kif5b-ret fusion molecules and uses thereof |
-
2012
- 2012-10-30 US US13/663,565 patent/US10023855B2/en active Active
- 2012-10-31 WO PCT/KR2012/009056 patent/WO2013066047A1/en not_active Ceased
- 2012-10-31 EP EP12845116.8A patent/EP2773673B1/en active Active
- 2012-10-31 JP JP2014538724A patent/JP6389124B2/ja active Active
- 2012-10-31 KR KR1020167010433A patent/KR101660235B1/ko active Active
- 2012-10-31 KR KR1020147013826A patent/KR101625139B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504299A5 (https=) | ||
| Dong et al. | The RNA-binding protein RBM3 promotes cell proliferation in hepatocellular carcinoma by regulating circular RNA SCD-circRNA 2 production | |
| Hu et al. | Mycobacterium tuberculosis RbpA protein is a new type of transcriptional activator that stabilizes the σ A-containing RNA polymerase holoenzyme | |
| Malik et al. | Targeting the MLL complex in castration-resistant prostate cancer | |
| Dews et al. | Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster | |
| Lulli et al. | Mir-370-3p impairs glioblastoma stem-like cell malignancy regulating a complex interplay between HMGA2/HIF1A and the oncogenic long non-coding RNA (lncRNA) NEAT1 | |
| KR20160138494A (ko) | Fgfr 융합물 | |
| JP2019512014A (ja) | がん診断法および治療法におけるｐｉＲＮＡを使用する組成物および方法 | |
| CN111630166B (zh) | 条件性-siRNA及其在治疗心肌肥大中的用途 | |
| JP2015513529A5 (https=) | ||
| JP2011511949A5 (https=) | ||
| Fasanaro et al. | ROD1 is a seedless target gene of hypoxia-induced miR-210 | |
| JP2017516458A5 (https=) | ||
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| US20210008070A1 (en) | Targeting minimal residual disease in cancer with cd36 antagonists | |
| Yang et al. | Circular RNA transcriptomic analysis of primary human brain microvascular endothelial cells infected with meningitic Escherichia coli | |
| US20250116034A1 (en) | Novel methods for rapid detection of immunogenic epitopes in biothreat agents and emerging pathogens for peptide vaccines and therapeutics | |
| Li et al. | Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn’s disease | |
| Zhang et al. | MicroRNA‐146‐5p promotes pulmonary artery endothelial cell proliferation under hypoxic conditions through regulating USP3 | |
| RU2013103466A (ru) | Блокада сигнализации ccl18 через ccr6 как терапевтический способ лечения при фиброзных заболеваниях и раке | |
| Jiang et al. | MiR-29c suppresses cell invasion and migration by directly targeting CDK6 in gastric carcinoma. | |
| Siena et al. | Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma | |
| KR20230088634A (ko) | 간암 특이적 바이오 마커 및 이의 용도 | |
| JP2014523736A5 (https=) | ||
| US11246868B2 (en) | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |